
ZIOPHARM Oncology, Inc. ZIOP
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
213 M |
Market Cap[1] |
$ 264 M |
EBITDA (LTM) |
$ 154 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | ||
|
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | ||
|
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | ||
|
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | ||
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market | ||
|
Xenon Pharmaceuticals
XENE
|
$ 41.4 | 2.35 % | $ 3.28 B | Nasdaq Global Select Market | ||
|
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | Nasdaq Global Market | ||
|
Zymeworks
ZYME
|
$ 31.45 | 2.08 % | $ 1.62 B | NYSE | ||
|
Adial Pharmaceuticals
ADIL
|
$ 3.15 | -35.42 % | $ 2.11 M | Nasdaq Capital Market | ||
|
ADMA Biologics
ADMA
|
$ 12.67 | -0.98 % | $ 3.02 B | Nasdaq Global Market | ||
|
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 3.66 | -1.35 % | $ 802 M | NYSE | ||
|
Daré Bioscience
DARE
|
$ 0.69 | 1.75 % | $ 7.71 M | Nasdaq Capital Market | ||
|
Fate Therapeutics
FATE
|
$ 1.78 | -8.51 % | $ 211 M | Nasdaq Global Market,SPB | ||
|
Greenwich LifeSciences
GLSI
|
$ 16.05 | -2.85 % | $ 217 M | Nasdaq Capital Market | ||
|
Halozyme Therapeutics
HALO
|
$ 103.0 | 0.08 % | $ 12.3 B | Nasdaq Global Select Market,SPB | ||
|
Hutchison China MediTech Limited
HCM
|
$ 15.34 | 0.1 % | $ 13.2 B | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | Nasdaq Global Select Market | ||
|
iBio
IBIO
|
$ 0.78 | -1.89 % | $ 81.2 M | NYSE American | ||
|
Kodiak Sciences
KOD
|
$ 108.01 | 0.85 % | $ 5.75 B | Nasdaq Global Market,SPB | ||
|
Karyopharm Therapeutics
KPTI
|
$ 0.02 | -54.5 % | $ 219 | Nasdaq Global Select Market | ||
|
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | ||
|
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | Nasdaq Global Select Market | ||
|
Catalyst Pharmaceuticals
CPRX
|
- | - | $ 3.85 B | Nasdaq Capital Market | ||
|
UroGen Pharma Ltd.
URGN
|
$ 25.32 | -3.78 % | $ 1.22 B | Nasdaq Global Select Market | ||
|
Catalyst Biosciences
CBIO
|
$ 13.91 | 1.9 % | $ 1.24 B | Nasdaq Capital Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
ADiTx Therapeutics
ADTX
|
- | - | $ 374 | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Apellis Pharmaceuticals
APLS
|
- | - | $ 5.18 B | Nasdaq Global Select Market,SPB | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 0.39 | 9.06 % | $ 28.6 K | Nasdaq Global Market | ||
|
Bio-Path Holdings
BPTH
|
- | - | $ 100 K | Nasdaq Capital Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | ||
|
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | ||
|
Cyclacel Pharmaceuticals
CYCC
|
- | -5.98 % | $ 34.1 M | Nasdaq Capital Market | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.